, Volume 60, Issue 5, pp 975–983 | Cite as

Management of Type 2 Diabetes Mellitus and Cardiovascular Risk

Lessons from Intervention Trials
  • Hannele Yki-Järvinen
Leading Article


Although the diagnosis of type 2 (noninsulin-dependent) diabetes mellitus is made when blood glucose levels exceed values which increase the risk of micro-vascular complications, macrovascular disease is the major complication of type 2 diabetes mellitus. Both epidemiological and prospective data have demonstrated that treatment of hyperglycaemia is markedly effective in reducing the risk of microvascular disease but is less potent in reducing that of myocardial infarction, stroke and peripheral vascular disease. Treatment of other cardiovascular risk factors, although by definition less prevalent than hyperglycaemia, appears to be more effective in preventing macrovascular disease than treatment of hyperglycaemia. In recent years, data from intervention trials have suggested that greater benefits with respect to the prevention of macrovascular disease can be achieved by effective treatment of hypertension and hypercholesterolaemia, and by the use of small doses of aspirin (acetylsalicylic acid) than by treating hyperglycaemia alone. On the other hand, the UK Prospective Diabetes Study (UKPDS), which examined the impact of intensive glucose and blood pressure (BP) control on micro- and macrovascular complications, is the only intervention trial to include only patients with type 2 diabetes mellitus. The UKPDS data, the epidemic increase in the number of patients with type 2 diabetes mellitus and their high cardiovascular risk have, however, initiated several new trials addressing, in particular, the possible benefits of treatment of the most common form of dyslipidaemia (high serum triglyceride and low high density lipoprotein cholesterol levels) in these patients. Type 2 diabetes mellitus is thus a disease associated with a high vascular risk, where the majority of patients need, and are likely to benefit from, pharmacological treatment of several cardiovascular risk factors provided treatment targets have not been achieved by life-style modification.


Macrovascular Disease Fibric Acid Derivative Hypertension Optimal Treatment Intensive Glucose Control Diastolic Blood Pressure Target 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Trovati M, Anfossi G. Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured vascular smooth muscle cells. Diabetologia 1998; 41: 609–22PubMedCrossRefGoogle Scholar
  2. 2.
    Yki-Järvinen H. Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet 1994; 343: 91–5PubMedCrossRefGoogle Scholar
  3. 3.
    Yki-Järvinen H. Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 1995; 38: 1378–88PubMedCrossRefGoogle Scholar
  4. 4.
    Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 1995; 25: 1327–32PubMedCrossRefGoogle Scholar
  5. 5.
    Zuanetti G, Latini R, Maggioni AP, et al. for the GISSI-3 investigators. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Data from the GISSI-3 study. Circulation 1997; 96: 4239–45Google Scholar
  6. 6.
    Moye LA, Pfeffer MA, Wun CC, et al. Uniformity of captopril benefit in the SAVE study: subgroup analysis. Survival and Ventricular Enlargement Study. Eur Heart J 1994; 15: 2–8Google Scholar
  7. 7.
    Torp-Pedersen C, Kober L, Carlsen J. Angio-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study. Am Heart J 1996; 132: 235–43PubMedCrossRefGoogle Scholar
  8. 8.
    Malmberg K for the DIGAMI study group. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997; 314: 1512–5PubMedCrossRefGoogle Scholar
  9. 9.
    The Bypass Angioplasty Revascularization Investigation (BARI) investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335: 217–25CrossRefGoogle Scholar
  10. 10.
    Van Belle E, Bauters C, Hubert E, et al. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997; 96: 1454–60PubMedCrossRefGoogle Scholar
  11. 11.
    Barsness GW, Peterson ED, Ohman EM, et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 1997; 96: 2551–6PubMedCrossRefGoogle Scholar
  12. 12.
    Kleinman NS, Lincoff AM, Kereiakes DJ, et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG investigators. Circulation 1998; 97: 1912–20Google Scholar
  13. 13.
    Stamler J, Vaccaro O, Neaton JD, et al., for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434–44PubMedCrossRefGoogle Scholar
  14. 14.
    The Hypertension in Diabetes Study Group. Hypertension in diabetes study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309–17CrossRefGoogle Scholar
  15. 15.
    The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413–46CrossRefGoogle Scholar
  16. 16.
    Haffner SM, D’Agostino RJ, Mykkanen L, et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999; 22: 562–8PubMedCrossRefGoogle Scholar
  17. 17.
    Harris MI, Hadden WC, Knowler WC, et al. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20–74 years. Diabetes 1987; 36: 523–34Google Scholar
  18. 18.
    Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937–42PubMedCrossRefGoogle Scholar
  19. 19.
    Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258–68PubMedCrossRefGoogle Scholar
  20. 20.
    Turner RC, Millns H, Neil HAW, et al., for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998; 316: 823–8PubMedCrossRefGoogle Scholar
  21. 21.
    Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656–60PubMedGoogle Scholar
  22. 22.
    Sobel BE. Insulin resistance and thrombosis: a cardiologist’s view. Am J Cardiol 1999; 84: 37J–41JPubMedCrossRefGoogle Scholar
  23. 23.
    Savage S, Estacio RO, Jeffers B, et al. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 1996; 19: 1243–8PubMedCrossRefGoogle Scholar
  24. 24.
    Neil A, Hawkins M, Potok M, et al. A prospective populationbased study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993; 16: 996–1003PubMedCrossRefGoogle Scholar
  25. 25.
    Gall MA, Borch-Johnsen K, Hougaard P, et al. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995; 44: 1303–9PubMedCrossRefGoogle Scholar
  26. 26.
    Jager A, Kostense PJ, Nijpels G, et al. Microalbuminuria is strongly associated with NIDDM and hypertension, but not with the insulin resistance syndrome: the Hoorn Study. Diabetologia 1998; 41: 694–700PubMedCrossRefGoogle Scholar
  27. 27.
    Fioretto P, Stehouwer CD, Mauer M, et al. Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia 1998; 41: 233–6PubMedCrossRefGoogle Scholar
  28. 28.
    UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 17: 713–20CrossRefGoogle Scholar
  29. 29.
    Curb JD, Pressel SL, Cutler JA, et al. for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older patients with isolated systolic hypertension. JAMA 1996; 276: 1886–92Google Scholar
  30. 30.
    Tuomilehto J, Rastenyte D, Birkenhäger WH, et al. for the Systolic Hypertension in Europa Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension [abstract]. N Engl J Med 1999; 340: 677–84Google Scholar
  31. 31.
    Hansson L, Lindholm LH, Niskanen L, et al. Principal results of the Captopril Prevention Project (CAPPP): effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. Lancet 1998; 353: 611–6CrossRefGoogle Scholar
  32. 32.
    Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645–52PubMedCrossRefGoogle Scholar
  33. 33.
    Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603PubMedCrossRefGoogle Scholar
  34. 34.
    Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT study group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet 1998; 351: 1755–62PubMedCrossRefGoogle Scholar
  35. 35.
    Drury PL. Diabetes and arterial hypertension. Diabetologia 1983; 24: 1–9PubMedCrossRefGoogle Scholar
  36. 36.
    Parving HH, Andersen AR, Smidt UM, et al. Diabetic nephropathy and arterial hypertension. Diabetologia 1983; 24: 10–2PubMedCrossRefGoogle Scholar
  37. 37.
    The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53CrossRefGoogle Scholar
  38. 38.
    The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 154–60CrossRefGoogle Scholar
  39. 39.
    Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–45Google Scholar
  40. 40.
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study [see comments]. JAMA 1998; 279: 1615–22PubMedCrossRefGoogle Scholar
  41. 41.
    Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998; 98: 2513–9PubMedCrossRefGoogle Scholar
  42. 42.
    Pyörälä K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin imrpoves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Survival Study (4S). Diabetes Care 1997; 20: 614–20PubMedCrossRefGoogle Scholar
  43. 43.
    Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57Google Scholar
  44. 44.
    Rader DJ, Haffner SM. Role of fibrates in the management of hypertriglyceridemia. Am J Cardiol 1999; 83: 30F–5PubMedCrossRefGoogle Scholar
  45. 45.
    Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: 160–78PubMedCrossRefGoogle Scholar
  46. 46.
    A strategy for arterial risk assessment and management in type 2 (non-insulin-dependent) diabetes mellitus. European Arterial Risk Policy Group on behalf of the International Diabetes Federation European Region. Diabetic Med 1997; 14: 611–21CrossRefGoogle Scholar
  47. 47.
    Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103–17PubMedCrossRefGoogle Scholar
  48. 48.
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–52CrossRefGoogle Scholar
  49. 49.
    UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65CrossRefGoogle Scholar
  50. 50.
    Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group [see comments]. N Engl J Med 1989; 321: 129–35CrossRefGoogle Scholar
  51. 51.
    ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 1998; 268: 1292–300Google Scholar
  52. 52.
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trails of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 80–106Google Scholar
  53. 53.
    Harpaz D, Gottlieb S, Graff E, et al. Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group. Am J Med 1998; 105: 494–9Google Scholar
  54. 54.
    Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34PubMedCrossRefGoogle Scholar
  55. 55.
    Yudkin JS, Chaturvedi N. Developing risk stratification charts for diabetic and nondiabetic subjects. Diabet Med 1999; 16: 219–27PubMedCrossRefGoogle Scholar
  56. 56.
    Pyörälä K, Wood D. Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced [editorial; comment]. Eur Heart J 1998; 19: 1413–5PubMedCrossRefGoogle Scholar
  57. 57.
    U.K. Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21: 87–92CrossRefGoogle Scholar
  58. 58.
    Yki-Järvinen H, Ryysy L, Nikkilä K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999; 130: 389–96PubMedGoogle Scholar
  59. 59.
    Valle T, Koivisto VA, Reunanen A, et al. Glycemic control in patients with diabetes in Finland. Diabetes Care 1999; 22: 575–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Department of MedicineUniversity of HelsinkiHelsinkiFinland

Personalised recommendations